Perrigo would consider Mylan bid at the right price

20 May 2015
mergers-acquisitions-big

The chief executive of Perrigo has said the company is willing to consider a takeover by Mylan (Nasdaq: MYL) if the terms were right, according to a Bloomberg report..

Joseph Papa noted, though, that the parties are presently “pretty far apart,” indicating that an agreement is not on the cards for the near future. Perrigo rejected Mylan’s offer only last month, in which Mylan offered $75 in cash per share, and 2.3 Mylan shares for each Perrigo share.

Perrigo believes that Mylan’s bid is worth $202 per share, due to Mylan’s share price being inflated, but Mylan has said the offer to Perrigo is worth $232.23 per share. Mr Papa added: “We believe they have substantially undervalued the company.” He declined to state what price Perrigo is seeking. He also said that Mylan’s previously-disclosed intention to go directly to Perrigo’s shareholders with a bid could happen by September 14. John Sheehan, the chief financial officer of Mylan, indicated that it is still answering questions from the Federal Trade Commission.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical